DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight” report provides comprehensive insights about 110+ Non-Alcoholic Fatty Liver Disease companies and 160+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non-Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Alcoholic Fatty Liver Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report
Request a sample and discover the recent advances in Non-Alcoholic Fatty Liver Disease Drugs @ Non-Alcoholic Fatty Liver Disease Pipeline Outlook Report
In the Non-Alcoholic Fatty Liver Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Non-Alcoholic Fatty Liver Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Non-Alcoholic Fatty Liver Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Non-Alcoholic Fatty Liver Disease commercial assessment and clinical assessment of the Non-Alcoholic Fatty Liver Disease pipeline products under development.
Non-Alcoholic Fatty Liver Disease Overview
Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders.
Find out more about Non-Alcoholic Fatty Liver Disease Analysis @ Non-Alcoholic Fatty Liver Disease Drugs
Non-Alcoholic Fatty Liver Disease Emerging Drugs Profile
Lanifibranor: Inventiva Pharma
Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARɣ and partial activation of PPARɣ. It is currently in the Phase III stage of development and is being developed by Inventiva Pharma.
Belapectin: Galectin Therapeutics
Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. It is currently in the Phase II/III stage of Clinical trial evaluation for Prevention of Esophageal Varices in NASH Cirrhosis.
ZED 1227: Dr. Falk Pharma GmbH
ZED 1227, is a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European countries and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is expected to improve liver fibrosis in patients with NAFLD. It is currently in the phase II stage of development and is being developed by Dr. Falk Pharma GmbH.
TVB-2640: Sagimet Biosciences
TVB-2640 is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II study for moderate to severe acne. It is currently in the phase II stage of development and is being developed by Sagimet Biosciences.
ALS-L1023: AngioLab
ALS L1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. The drug is currently being investigated in Phase II clinical trials for the treatment of patients with Nonalcoholic Steatohepatitis.
MN-001: MediciNova
MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. MN-001 has also known to reduce fibrosis in multiple animal models. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Nonalcoholic Steatohepatitis.
Non-Alcoholic Fatty Liver Disease Therapeutics Assessment
There are approx. 120+ Non-Alcoholic Fatty Liver Disease companies which are developing the Non-Alcoholic Fatty Liver Disease therapies. The Non-Alcoholic Fatty Liver Disease companies which have their Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage, i.e. phase III include, Inventiva Pharma.
Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Dive deep into rich insights for new Non-Alcoholic Fatty Liver Disease, visit @ Non-Alcoholic Fatty Liver Disease Treatment Landscape
Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as
Scope of the Non-Alcoholic Fatty Liver Disease Pipeline Report
For further information on the Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics, reach out @ Non-Alcoholic Fatty Liver Disease Therapeutics Segmentation
Table of Content
Find out more about Non-Alcoholic Fatty Liver Disease Therapeutics Assessment @ Non-Alcoholic Fatty Liver Disease Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/cystic-fibrosis-market
